Drug
Vidofludimus clinical trials
Includes 7 studies of Vidofludimus-calcium and 1 study of Vidofludimus calcium monohydrate.
- studies test it
- 10
- open now
- 0
- in phase 3
- 3
- first study started
- 2009
How studies write it
Studies that test it under each name
Name
Studies by the year they started
10 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 8
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 2
Immunic AG (6) · 4SC AG (2) · University Hospitals Coventry and Warwickshire NHS Trust (1) · Elizabeth Carey (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses vidofludimus is read from its arms, and is right about nine times in ten.
Testing it · 10
- Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisActive, not recruitingPhase 3Immunic AGNCT05134441Written as IMU-838 tablets
- Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisActive, not recruitingPhase 3Immunic AGNCT05201638Written as IMU-838 tablets
- A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)CompletedPhase 2/3Immunic AGNCT04379271Written as IMU-838
- Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple SclerosisActive, not recruitingPhase 2Immunic AGNCT05054140Written as IMU-838
- MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)Active, not recruitingPhase 2Immunic AGNCT03846219Written as IMU-838 (30 mg/day)
- Phase 2 Dose-finding IMU-838 for Ulcerative ColitisTerminatedPhase 2Immunic AGNCT03341962Written as IMU-838
- IMU-838 and Oseltamivir in the Treatment of COVID-19CompletedPhase 2University Hospitals Coventry and Warwickshire NHS TrustNCT04516915Written as IMU-838
- Vidofludimus Calcium for Primary Sclerosing CholangitisCompletedPhase 2Elizabeth CareyNCT03722576Written as Vidofludimus calcium
- SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid ArthritisCompletedPhase 24SC AGNCT01010581Written as SC12267 (4SC-101)
- SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel DiseaseCompletedPhase 24SC AGNCT00820365Written as SC12267 (4SC-101)
Codes
What other systems call vidofludimus · ClinicalTrials.gg INT005740
- MeSH (NLM) C553728vidofludimusOne source NLM
- UNII (FDA) 8Y1PJ3VG81VIDOFLUDIMUSConfirmed FDA, NLM, Wikidata
- Wikidata Q27271184vidofludimusConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152873VidofludimusOne source FDA
- DrugBank DB15446One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C553728 | vidofludimus | One source NLM |
| UNII (FDA) | 8Y1PJ3VG81 | VIDOFLUDIMUS | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27271184 | vidofludimus | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152873 | Vidofludimus | One source FDA |
| DrugBank | DB15446 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.